Alright last post I swear. Craig will be deleted a
Post# of 157806
(Total Views: 555)
Posted On: 08/16/2022 4:47:53 PM
Alright last post I swear. Craig will be deleted and I will also not post about this again but for all investors I want to make this very clear.
It is up to the company to disclose any type of pertinent information from the FDA. For example like the question I brought up earlier.
The clinical hold CAN be lifted and we would not know about it until the company disclosed such information.
The company could possibly not update us on information like the clinical hold or type C meeting even though they could be completed. The FDA leaves that up to the company. Whether or not these things have been completed I have no idea.
I just want it to be clear as mud, that it is not the FDAs job to tell us a clinical hold has been lifted. It’s the companies job to do so. This is directly from a pharmacist at the FDA I spoke to on the phone and another lady I spoke to on the phone at the FDA. Feel free to call them yourself.
It is up to the company to disclose any type of pertinent information from the FDA. For example like the question I brought up earlier.
The clinical hold CAN be lifted and we would not know about it until the company disclosed such information.
The company could possibly not update us on information like the clinical hold or type C meeting even though they could be completed. The FDA leaves that up to the company. Whether or not these things have been completed I have no idea.
I just want it to be clear as mud, that it is not the FDAs job to tell us a clinical hold has been lifted. It’s the companies job to do so. This is directly from a pharmacist at the FDA I spoke to on the phone and another lady I spoke to on the phone at the FDA. Feel free to call them yourself.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36